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LYAR, a novel nucleolar protein 
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A cDNA encoding a novel zinc finger protein has been isolated from a mouse T-cell leukemia line on the 
basis of its expression of a Ly-1 epitope in a kgtl 1 library. The putative gene was mapped on mouse 
chromosome 1, closely linked to Idh-1, but not linked to the Ly-1 (CD5) gene. The cDNA is therefore named 
Ly-1 antibody reactive clone (LYAR). The putative polypeptide encoded by the cDNA consists of 388 amino 
acids with a zinc finger motif and three copies of nuclear localization signals. Antibodies raised against a 
LYAR fusion protein reacted with a protein of 45 kD on Western blots and by immunoprecipitation. 
Immunolocalization indicated that LYAR was present predominantly in the nucleoli. The LYAR mRNA was 
not detected in brain, thymus, bone marrow, liver, heart, and muscle. Low levels of LYAR mRNA were 
detected in kidney and spleen. However, the LYAR gene was expressed at very high levels in immature 
spermatocytes in testis. The LYAR mRNA is present at high levels in early embryos and preferentially in fetal 
liver and fetal thymus. A number of B- and T-cell leukemic lines expressed LYAR at high levels, although it 
was not detectable in bone marrow and thymus. During radiation-induced T-ceU leukemogenesis, high levels 
of LYAR were expressed in preleukemic thymocytes and in acute T leukemia cells. Fibroblast cells 
overexpressing the LYAR cDNA from a retrovirus vector, though not phenotypically transformed in vitro, had 
increased ability to form tumors in nu/nu mice. Therefore, LYAR may function as a novel nucleolar 
oncoprotein to regulate cell growth. 
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Oncogenic transformation of cells leads to a number of 
changes in cellular metabolism, physiology, and mor- 
phology. One of the major changes is the pleomorphism 
and hyperactivity of the nucleolus (Yeoman et al. 1976; 
Busch et al. 1979, 1986). Nucleolar proteins have been 
identified that are specifically expressed in actively di- 
viding cells and tumor cells (Reddy et al. 1989). The 
functions of these proteins are not clear, and it has been 
speculated that they may be involved in cell growth reg- 
ulation (Tan 1982; Mathews et al. 1983) and in transcrip- 
tional control (Dynan and Tjian 1983). 
The precise molecular pathways and secondary 
changes leading to malignant ransformation for most 
cell types are not clear. A number of cases have been 
reported in which altered expression or activity of some 
proteins with putative DNA-binding motifs are found in 
some tumors or leukemias. For example, chromosomal 
translocations involving lyl-1 [a protein with a putative 
DNA-binding motif (Mellentin et al. 1989)] and the fu- 
sion proteins between RAR~ and PML [a zinc finger- 
encoding ene (de The et al. 1991; Goddard et al. 1991)] 
are detected in some leukemic cell lines. In two recent 
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reports, a zinc finger protein has been identified which, 
when overexpressed, appears to cooperate with the myc 
oncogene to induce B-cell leukemias in transgenic mice 
(Haupt et al. 1991; van Lohuizen et al. 1991). 
The zinc finger domain is a sequence-specific DNA- 
binding motif in a family of proteins that was first iden- 
tified in the Xenopus laevis transcription factor IIIA 
(Miller et al. 1985). Substantial evidence has established 
these proteins a a class of trans-acting molecules with 
regulatory roles in cellular growth and differentiation. 
Here, we report a eDNA isolated from a T-cell leukemia 
line which encodes a putative nuclear protein with zinc 
finger motifs. We present evidence that the protein is 
localized in the nucleolus of cells. Expression of the gene 
is induced during radiation-induced thymic leukemo- 
genesis in mice. Over-expression of the eDNA in NIH- 
3T3 cells increases their tumorigenic potential in nu/nu 
mice. 
Results 
Isolation of a eDNA encoding a zinc finger protein 
from a mouse T-cell leukemia line 
In an attempt o clone the T-cell surface marker Ly-1 
(CD5) several years ago (Hershberger 1989), a Kgtll li- 
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brary from the leukemic T cell EL4 was screened with 
the anti-Ly-1 monoclonal antibody 53.7 (Ledbetter and 
Herzenberg 1979]. The Ly-1 antibody reactive clone 
(LYAR) was characterized and sequenced. It was ruled 
out as encoding Ly-1 by chromosomal mapping {see be- 
low]. Comparison of LYAR to the Ly-1 sequences, ub- 
sequently elucidated by others {Huang et al. 1987), 
showed that they encoded polypeptides with no signifi- 
cant similarity. 
The LYAR clone encodes a l164-bp open reading 
frame consisting of 388 amino acids (Fig. 1A}. A se- 
quence similarity search of the gene bank data bases re- 
vealed no significant similarity to any known genes ei- 
ther at the DNA or at the amino acid levels (data not 
shownl. Further inspection of the encoded polypeptide 
revealed that two putative zinc finger domains are 
present in the first 60 amino acids (Fig. 1A, underlined). 
Both of the zinc finger motifs are similar to the standard 
zinc finger consensus equence (Berg 1986), although the 
space between the last two zinc-binding residues (Cys or 
His] is two instead of three amino acids. 
Recently, anew family of zinc finger proteins has been 
identified whose spacing between the last two zinc-bind- 
ing residues consists of two instead of three amino acids 
{Fig. 1B; Goddard et al. 1991; Haupt et al. 1991; van 
Lohuizen et al. 1991). These proteins all have eight zinc- 
binding residues (Cys or His) in a cluster (C4HC3) at their 
amino termini. The putative zinc finger domains at the 
amino terminus of LYAR fit the consensus of this new 
class of zinc finger motifs {Fig. 1B1, although the LYAR 
domain has the His residue in a different position 
{C6HC). Overall, this Cys/His motif seems to character- 
ize proteins that interact with DNA. Most of the pro- 
teins are implicated in cell proliferation and tumorigen- 
esis, and other regulatory functions. 
Three copies of nuclear localization signals (NLS} are 
also detected in the protein (Fig. 1A, C]. One is almost 
identical to the first NLS identified in the SV40 T anti- 
gen {Kalderon et al. 1984a, b). The other two are bipartite 
nuclear localization signals (BNLSI similar to the ones 
identified in nucleoplasmin and thyroid f~-receptor {Rob- 
bins et al. 1991). Thus, the LYAR eDNA appears to en- 
code a nuclear protein with a putative DNA-binding mo- 
tif. 
A sequence search for conserved motifs also revealed 
that LYAR has a potential site for tyrosine phosphoryla- 
tion immediately following the second zinc finger (dou- 
ble underlined in Fig. 1A1. A potential Ser residue for 
cAMP-dependent protein kinase is also detected at the 
carboxyl terminus (Fig. 1A, carboxyl terminus under- 
linel. In addition, a stretch of amino acids is found to be 
mostly charged residues (32 of 47} with a positive net 
charge {ll negative, 21 positive residues; Fig. 1A, wavy 
underline). 
Chromosomal location of the LYAR gene 
The chromosomal location of the LYAR gene in mice 
was established using the BXD recombinant inbred 
strains (Bailey 19711. A restriction fragment length poly- 
morphism (RFLP1 for LYAR between the BXD parental 
strains C57B1/6 and DBA was identified, and this was 
used to determine the strain distribution pattern of the 
LYAR locus in 21 BXD mice (Table 1}. The strain distri- 
bution pattern for LYAR exactly matched that of isoci- 
trate dehydrogenase-1 {Idh-ll on chromosome 1, imply- 
ing that these loci are tightly linked (P>0.991. Adjacent 
loci on chromosome 1 also showed significant linkage, 
which diminished with increasing distance from Idh-I. 
The proximal chromosome 1 markers gave the best 
match to LYAR of 144 loci on 16 chromosomes {Taylor 
1989). 
L YAR, a 45-kD protein, is localized predominantly 
in the nucleolus 
Antibodies were raised against a LYAR fusion protein 
produced in bacteria. The purified antibodies pecifically 
recognized a protein of 45 kD from EL4 cells, which was 
not detected in a bone marrow-derived stromal cell line 
(AC6) on Western blot (Fig. 2A, B}. 
By immunoprecipitation of labeled cell extracts, it was 
shown that the antibody reacted with a protein of -45 
kD, which was not detected in AC6 cells, and the pre- 
immune antiserum did not react with this protein (Fig. 
2C). The mobility of the protein on SDS-PAGE did not 
change under reducing or nonreducing conditions (data 
not shownl. 
Indirect immunofluorescence staining was performed 
to localize the LYAR protein in mouse cell lines and in 
COS-7 cells transfected with the LYAR eDNA. The 
LYAR protein was localized predominantly in some sub- 
compartments of the nuclei of T or B leukemia cells 
(data not shown). Using mouse embryonic fibroblast (EF1 
cells (Fig. 3A), it was shown clearly that the LYAR pro- 
tein was localized in the nuceoli of the nucleus, which 
was visualized by staining DNA with Hoechst 33342. 
In addition, COS-7 cells transiently transfected with 
the LYAR cDNA also showed predominantly nucleolar 
staining (Fig. 3B). COS-7 cells transfected with the vector 
plasmid DNA did not give any detectable staining {data 
not shown). This indicates that the antibody was specific 
to the protein encoded by the LYAR cDNA. A few of the 
LYAR-expressing cells, however, seemed to express 
LYAR at higher levels, and LYAR was localized both in 
the nucleolus and in the nucleoplasm. Interestingly, the 
nucleoli of these cells appeared to be more organized 
along the nuclear membrane (see arrows in Fig. 3B), per- 
haps as a result of overexpression f LYAR in these cells. 
In actively dividing mouse EF cells, the LYAR protein 
is present mostly in the nucleolus. However, in some 
cells undergoing mitosis with condensed chromosomal 
DNA, LYAR protein is localized throughout the cells. 
The LYAR protein appears to be excluded from the con- 
densed chromosomal DNA (Fig. 3C, c). The rhodamine 
immunofluorescence signal (red] of LYAR appears to be 
excluded from nuclear compartments where high levels 
of DNA (blue or white} are detected (Fig. 3C, c). This 
indicates that LYAR is probably not an integral part of 
the chromosomes. 
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Figure 1. Molecular structure of the 
LYAR gene. {AI Nucleotide and deduced 
amino acid sequences of the LYAR cDNA. 
The zinc finger region is underlined. The 
double underline indicates a potential Tyr 
phosphorylation site. The region under- 
scored by a wavy line consists of 47 resi- 
dues with 32 charged ones (11 negative, 21 
positivel. The three putative NLS are 
marked with bold letters [(BNLSJ bipartite 
nuclear localization signal; INLSI SV40 
T-type nuclear localization signal)]. A pu- 
tative phosphorylation site for cAMP-de- 
pendent kinase is marked at the carboxyl 
terminus. IB} The zinc finger motifs of 
LYAR and a new family of proteins. The 
residues conserved in all proteins are 
boxed and defined as the consensus, ex- 
cept Pro IP}, which is not conserved in all 
the proteins. IX} Any amino acid. Residues 
conserved in LYAR are in bold letters. Se- 
quences not cited in the text are the bac- 
ulovirus early proteins CG30 (Thiem 
and Miller 1989J and PE-38 {Krappa nd 
Knebel-Morsdorf 1991 ), a trypanosome pro- 
tein with a leucine repeat motif, T-LR 
ISmiley et al. 1990j, and the SS-A/Ro pro- 
tein {Chan et al. 1991), which is part of a 
nuclear ribonucleoprotein particle. {CI 
The putative NLS in the LYAR protein. As 
marked in Fig. 1A, NLS is aligned with 
that of the SV40 T. BNLS 1 and BNLS2 are 
aligned with the NLS of thyroid [~-receptor 
and nucleoplasmin, respectively. IXJ Any 
amino acid. 
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Table 1. LYAR pattern distribution in BXD and linkage analysis 
BXD 1 5 6 8 9 11 12 14 15 16 18 19 21 22 24 25 27 28 29 30 31 
LYAR B B D D B B B B D D B D B B B D D D D D B 
Chromosome 1 locus Distance to Idh-1 (cm} Number of differences Probability of linkage 
Aox-1 6.43 - 1.55 1/21 >0.99 
Idh-1 0 0/21 >0.99 
Lsh 11.46 --- 3.59 6/21 />0.95 
Pep-3 23.31 +- 1.81 7/21 <0.90 
Mls 31.92 -+ 6.01 9/21 <0.90 
Strain distribution pattern of the LYAR RFLP among the BXD recombinant inbred strains C57B1/6 {B} and DBA {D). The summary of 
the strain distribution comparisons to loci on chromosome 1, listed in proximal to distal order, is based on data given in Taylor (1989). 
The genetic distances to Idh-1 are from published results (Davidson et al. 19891, using the combined male and female recombination 
data. Probability of linkage was calculated by the x 2 distribution. 
The LYAR mRNA is detected in a number of T and- 
B leukemia cells but not in most  adult mouse tissues 
To investigate the expression pattern of LYAR in T- and 
B-cell leukemias, we first examined its expression in a 
number of cell l ines by Northern blot analyses (Fig. 4A}. 
High levels of LYAR mRNA were detected in all leuke- 
mic T (BW, EL4, and VL3.1) and leukemic B (L1-2, 200-2 
and RAW112) lineage cell l ines tested but not in a bone 
marrow-derived stromal cell l ine {AC6) or in an interleu- 
kin-2 (IL-2)-dependent CTL l ine (AR1). Thus, LYAR 
seemed to be expressed at high levels in the transformed 
leukemia cells tested. 
Expression of LYAR in different issues of adult mice 
was also examined (Fig. 4B). By Northern blot analyses, 
LYAR mRNA was not detected in brain, thymus,  liver, 
bone marrow, heart, or muscle. Low levels of expression 
were detected in kidney and spleen, and high levels of 
LYAR mRNA were detected in testis. In situ hybridiza- 
t ion with the LYAR cDNA probes confirmed the expres- 
sion patterns in mouse primary tissues (see below and 
data not shown). This indicated that the T- and B-cell 
leukemia lines tested were induced to express the LYAR 
gene sometime during or after their transformation. 
LYAR expression during radiation-induced T-cell 
leukemogenesis 
As ment ioned above, LYAR mRNA was not detectable 
in thymus or bone marrow but was highly expressed in 
Figure 2. Characterization f the LYAR protein. (A) Western blot analysis of the LYAR protein in EL4 cells with the antisera. Total 
cell extract from 106 cells was loaded in each lane and Western blotted. (Left} Anti-LYAR specific antiserum; {rightl preimmune serum. 
(Lane 1} 1 : 1000 dilution; {lane 2) 1 : 2000 dilution; {lane 3) 1 : 5000 dilution. (mLy) Mouse LYAR protein. (B) Western blot analysis 
of EL4 and AC6 cells. As in A, anti-LYAR-specific antiserum was used at 1 : 2000 dilution. {Lane 1) Extract from EL4 cells~ (lane 2) 
extract from AC6 cells. (C) Immunoprecipitation of LYAR from EL4 and AC6 cells. Cell extracts labeled with [3SS]methionine (5 x 106 
cpm) from EL4 or AC6 cells were precipitated with preimmune serum (lanes 1} or anti-LYAR serum {lanes 2). (mLY) Mouse LYAR 
protein. 
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all of the T and B lineage leukemia cells tested (Fig. 
4A,B). We therefore decided to test whether the expres- 
sion of LYAR occurred in the preneoplastic orneoplastic 
stages of radiation-induced thymic leukemogenesis in
mice. C57B1/Ka mice were exposed to the standard 
weekly leukemogenic X-ray radiation protocol (Kaplan 
and Brown 1954]. RNA isolated from thymocytes at dif- 
ferent stages following irradiation (12-16 weeks after ir- 
radiation for the preleukemic thymocytes or 20-24 
weeks after irradiation for the leukemic thymocytes) 
was blotted and probed with a LYAR-specific probe (Fig. 
4C). High levels of LYAR mRNA were detected in thy- 
mic populations containing preleukemic thymocytes, as 
well as in acute leukemic thymocytes. 
The increased LYAR mRNA detected could be the re- 
sult of induction of the LYAR gene in preleukemic or 
leukemic thymocytes. Alternatively, it could also be at- 
tributable to expansion of a minor thymocyte population 
expressing high levels of LYAR in the normal thymus. 
To investigate the latter possibility, in situ hybridization 
was performed with thymus sections from normal mice 
(Fig. 4D). No cells in the thymus were found to express 
high levels of the LYAR message. Therefore, expression 
of the LYAR gene appeared to be highly induced early 
during the thymic leukemogenesis process. 
Expression of the L YAR gene during embryonic 
development 
The LYAR gene was expressed at high levels in mouse 
embryonic stem (ES) cells (Fig. 5A, lane 1). Analyses of 
RNA isolated from day 9 and day 13 embryos also de- 
tected high levels of LYAR mRNA (Fig. 5A, lanes 2,3]. 
Low levels of LYAR mRNA were detected in adult 
spleen, as shown above in Figure 4B and in Figure 5A 
(lane 4). 
To localize specific tissues expressing LYAR, early 
embryos were studied for LYAR expression by in situ 
hybridization. The LYAR mRNA was detected in day 10 
fetal liver (Fig. 5B) and day 13 fetal thymus (Fig. 5C). No 
significant levels of hybridization were detected in fetal 
heart at either stage. Expression of LYAR was also de- 
tected in fetal livers and fetal thymuses of other fetal 
developmental stages, and in some other tissues uch as 
vertebrae and lung (L. Su and I.L. Weissman, in prep.). 
Therefore, the LYAR gene is expressed in early embryos 
and preferentially in some tissues, including fetal liver 
and fetal thymus, where fetal hematopoiesis  occur- 
ring. 
The LYAR gene is expressed at very high levels 
in immature spermatocytes 
In adult testis the LYAR mRNA was present at a very 
high level (Fig. 4B). In situ hybridization was performed 
to examine what cell types in the testis express the 
LYAR gene. As shown in Figure 6, LYAR-positive cells 
appeared to reside at the basal layer of the seminiferous 
tubules, where the immature spermatocytes are located 
(Fig. 6A). The Sertoli cells, interstitial cells (Leydig cells), 
the mature, and maturing spermatozoa did not express 
detectable vels of LYAR (Fig. 6A, a,b]. The sense probe, 
which served as negative control f r specific hybridiza- 
tion, showed no hybridization signal in the testis (Fig. 
6A, c, dl. 
To confirm that the LYAR protein is expressed in m- 
mature spermatocytes, immunofluorescence staining of 
testis sections with the anti-LYAR antibodies was per- 
formed (Fig. 6B). The primary and secondary spermato- 
cytes are specifically labeled, consistent with the in situ 
hybridization results. 
To confirm that only the germ cells in testis expressed 
the LYAR gene, in situ hybridization was performed 
with testis sections from the germ cell-deficient mouse 
(W/WV). It is known that W/W v mice are sterile because 
they lack germ cells, and the nongerm cells of the testis 
are all present (Coulumbre and Russell 1954). As ex- 
pected, no LYAR-positive cells were detected in testis 
from W/W v mice (Fig. 6C]. 
LYAR is a novel nucleolar protein with oncogenic 
potential 
We have demonstrated that LYAR is a nucleolar protein 
with a putative DNA-binding domain. Expression of the 
LYAR gene seems to correlate with abnormal cell 
growth. The oncogenic potential of LYAR was tested by 
overexpressing the LYAR eDNA in a mouse fibroblast 
cell line (NIH-3T3) via a retrovirus vector. Figure 6 
shows that two independent clones stably expressing the 
LYAR eDNA, Vly12 and Vly36 (Fig. 7A, lanes 1,2), ex- 
pressed much higher levels of LYAR proteins than the 
control cells expressing the neomycin resistance gene 
(Fig. 6A, lane 3) or the parental NIH-3T3 ceils (data not 
shown). 
The cells expressing high levels of LYAR (Vlyl2, 
Vly22, Vly 361, although not morphologically trans- 
formed in vitro (data not shown), showed increased abil- 
ity {i.e., higher frequency and shorter latent period) to 
form tumors at the sites of injection than the control 
Figure 3. Subcellular localization of LYAR. (AI LYAR is localized in the nucleolus. Mouse EF cells were stained with anti-LYAR 
antiserum (a,c,e) or preimmune serum (b,d,f). la, b) Phase-contrast pictures how the cellular morphology; ic, d) fluorescence signals of 
anti-LYAR staining; le,f) DNA {Hoechst dyel staining. Thearrows in a,c, and e indicate one of the nucleoli stained with the anti-LYAR 
antibody. (BI The LYAR eDNA encodes the nucleolar protein reactive with the anti-LYAR antibody. COS-7 cells transiently expressing 
the LYAR eDNA were stained with the anti-LYAR monoclonal ntibody. {a) Transfected cells stained with the anti-LYAR monoclonal 
antibody staining, (magnification, 64 x ); (b) as in a (magnification, 256 x); (c) phase contrast of b. The arrows how the nucleoli of some 
LYAR-positive cells. (C) LYAR localization during cell mitosis. Actively dividing mouse EF cells were stained with polyclonal 
antiserum. (a)Anti-LYAR signals (rhodamine); Ib)DNA (Hoechst dye) staining; (c)double exposure of both the anti-LYAR signals (red) 
and the DNA-staining signals(blue and white). 
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Figure 4. Induction of LYAR mRNA in 
leukemia cells and during radiation-in- 
duced T-cell leukemogenesis. Total cellu- 
lar RNA (15 ~gl was loaded on the gel and 
probed with either the LYAR cDNA or a 
human f~-actin cDNA. The arrowheads 
mark the 18S and 28S rRNA bands. (AJ 
LYAR mRNA in different cell lines. AR1 
(lane 1 J, An IL-2-dependent CTL line; L1-2 
(lane 2), RAWll2 (lane 3) and 200-2 (lane 
4), three pre-B cell leukemia lines; BW 
(lane 51, VL3.1 (lane 6), and EL4 (lane 7), 
three T-cell leukemia lines. (LY) LYAR 
mRNA; (AC) actin mRNA. (B] LYAR 
mRNA in different mouse tissues. (Lane t } 
Spleen (SP}; (lane 2) brain (BR]; (lane 31 thy- 
mus [TH}; (lane 4) liver [LIV); (lane 5) bone 
marrow (BM); (lane 6) kidney (KID]; (lane 
7) heart (HRT}; (lane 8J testis (TES); (lane 
9) muscle (MUS}i (lane 10) bone marrow- 
derived stromal cell line (AC6). {C] LYAR 
mRNA from mouse thymocytes during ra- 
diation-induced thymic leukemogenesis. 
(Lane 11 Preleukemic thymocytes (preTH); 
(lane 2) leukemic thymocytes (leuTH); 
(lane 31 EL4 cells; (lane 4} normal thymo- 
cytes (TH). (D) Analysis of LYAR mRNA 
in normal mouse thymus by in situ hy~ 
bridization. Thymus sections of normal 
mouse were hybridized with LYAR ribo- 
probes. (a, bJ LYAR antisense probe; (c,d} 
LYAR sense probe; [a,c) phase-contrast 
pictures howing the tissue section; (b,d] 
dark-field pictures showing any LYAR 
mRNA signals (bright white grains). 
cells (Neo 1, Vneo22, Vneo45), when their tumor-forming 
potential was tested in nu/nu mice iTable 2). Tumors 
derived from Vlyl2 were shown to express the LYAR 
eDNA at high levels (data not shown) and were typical 
fibrosarcomas (Fig. 7B). The tumor cells could be retrans- 
ferred to form tumors efficiently in other nu/nu mice 
(Table 2}. 
The cells expressing the neo gene from the retroviral 
vector (Vneo22 and Vneo451 or from an expression plas- 
mid (Neol) did not give rise to any visible tumors until 
the fourteenth week after injection. By that time, some 
of the mice with tumors from the LYAR eDNA-express- 
ing cells had died from tumors that were usually 3-4 cm 
in diameter. Therefore, overexpression of the LYAR 
eDNA in NIH-3T3 fibroblast cells rendered them more 
tumorigenic, indicating that LYAR is a novel nucleolar 
protein that can be involved in cell growth regulation. 
Discuss ion  
LYAR is a eDNA isolated from a T-cell leukemia line 
encoding a novel nuclear zinc finger protein 
A eDNA was isolated and characterized from a T-cell 
leukemia, which encoded a polypeptide cross-reactive 
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Figure 5. Detection of LYAR mRNA during early fetal development. (A) Northern blot analysis of LYAR mRNA in early embryos. 
RNA isolated from ES cells (lane I), day 9 whole embryo (Eg, lane 2), day 13 whole embryo (El3, lane 31 or adult spleen ISp, lane 4) 
was hybridized with a LYAR-specific probe {LY, top) or a human actin probe (AC, bottom). (B) Detection of LYAR mRNA in day 10 
fetal liver by in situ hybridization. The bright-field picture demonstrated that high levels of LYAR NA were detected Iblack grains) 
in fetal liver iLv) but not in fetal heart {Htl. {a) Day 10 embryo section hybridized with a LYAR sense probe as a background control; 
{b) day 10 embryo section hybridized with a LYAR antisense probe. Magnification, 19 x. (C) Detection of LYAR mRNA in day 13 fetal 
thymus by in situ hybridization. The bright-field picture showed high levels of LYAR RNA present in day 13 fetal thymus (Th) but 
not in fetal heart (Ht). (a) Day 13 embryo section hybridized with a LYAR sense probe as a background control; (b) day 13 embryo 
section hybridized with a LYAR antisense probe. Magnification, 94 x. 
with the anti-Ly-1 monoclonal antibody 53.7. The puta- 
tive gene was mapped by RFLP on mouse chromosome 1 
and was not the Ly-1 gene. The LYAR clone encoded a 
protein that has a unique zinc finger motif within the 
first 60 amino acid residues and three copies of NLS (Fig. 
1). 
A new family of zinc finger proteins has been identi- 
fied recently (Goddard et al. 1991). Like LYAR, these 
proteins all have eight zinc-binding residues in a cluster 
at the amino terminus (Fig. 1B). Most of the proteins in 
this family have been implicated in regulating cell 
growth or gene expression. For example, PML (de The et 
al. 1991~ Goddard et al. 1991), bim-1 (Goebl 1991; Haupt 
et al. 1991; van Lohuizen et al. 1991), MEL-18 (Tagawa et 
al. 1990; Goebl 19911, and rfp (Takahashi et al. 1988) are 
probably involved in cell transformation; IE 110 (Perry et 
al. 1986), VZV61 (Damson and Scott 1986), and Rpt-1 
(Pataraca et al. 1988) are believed to be involved in reg- 
ulating gene expression; and RAG-1 {Schatz et al. 1989) 
and RAD-18 (Jones et al. 1988) are involved in site-spe- 
cific DNA recombination and DNA repair, respectively. 
The three copies of putative NLS present in LYAR 
suggest hat its nuclear localization may be of interest 
(Fig. 1C]. The SV40 T antigen signal, which is sufficient 
to direct most, but not all, proteins into the nucleus, 
requires other NLS motifs to transport some proteins 
(Richardson et al. 1986; Greenspan et al. 1988; Morin et 
al. 1989). Thus, LYAR may use these multiple copies of 
NLS to direct its nuclear and/or subnuclear localization. 
Multiple copies of NLS may also play a role in regulated 
nuclear localization. For example, two copies of NLS 
have been reported in the glucocorticoid receptor, whose 
nuclear localization is regulated by binding to steroid 
hormones (Picard and Yamamoto 1987; Picard et al. 
1990). 
Nucleolar localization and the putative DNA-binding 
domain of L YAR 
Immunolocalization of LYAR in different cells clearly 
showed that LYAR is predominantly ocalized in the nu- 
cleolus (Fig. 3). A putative NLS consisting of mostly pos- 
itively charged residues has been identified (Siomi et al. 
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Figure 6. Localization of LYAR-express- 
ing cells in mouse testis. (A) In situ hybrid- 
ization detection of the LYAR mRNA in 
mouse testis. (a,b) LYAR antisense probe; 
(c,d) LYAR sense probe, a and c are bright- 
field pictures showing the morphology; b 
and d are dark-field pictures showing the 
LYAR mRNA hybridization signals (white 
grains). (st) Sertoli cells; (s) spermatozoa; 
(ms) maturing spermatozoa. (B) Detection 
of the LYAR protein in mouse testis by im- 
munofluorescence staining. (a)Testis sec- 
tion was stained with preimmune serum, 
(magnification, 22x); (b] testis section 
stained with anti-LYAR specific antise- 
rum, (magnification, 22x}; fc)anti-LYAR 
specific antiserum, (magnification, 112 x). 
(st) Sertoli ceils; (s) spermatozoa; (ms} ma- 
turing spermatozoa. (C) Analysis of LYAR 
mRNA in W/W v mouse testis by in situ 
hybridization. (a) Phase contrast of the tes- 
tis section; (b) dark-field picture of testis 
section hybridized with the LYAR anti- 
sense probe; (c} dark-field picture of testis 
section hybridized with the LYAR sense 
probe. 
1988). The charged region in LYAR (Fig. 1AJ has a net 
positive charge that might  serve as a NLS. 
The subcellular location of a protein usual ly impli- 
cates its potential function in the cell. According to our 
current understanding of the nucleolus, LYAR may be 
involved in the following processes: (1) r ibosomal gene 
GENES & DEVELOPMENT 743 
Su et al. 
Figure 7. (A} Western blot analysis of NIH-3T3 cells expressing LYAR cDNA. Cell extract from 106 NIH-3T3 cells expressing LYAR 
cDNA Vlyl2 (lane 1) and Vly36 (lane 2) and cells expressing the neomycin gene Vneo45 (lane 3), and AC6 {bone marrow stromal cell 
line, lane 4} were analyzed with anti-LYAR serum at 1 : 2000 dilution. (mLy) Mouse LYAR protein. (B) Histology of the fibrosarcoma 
derived from Vly12 in nu/nu mice. 
transcription; (2)rRNA processing; (3)ribosome assem- 
bly; or (41 protein transport between the nucleus and 
cytoplasm {Meier and Blobel 1990, 1992). 
The zinc finger motifs in LYAR and the fact that the 
glutathionine s-transferase (GST)-LYAR fusion protein 
can bind to double-stranded DNA with high affinity (L. 
Su and I.L. Weissman, unpubl.) strongly suggest that 
LYAR is a DNA-binding protein. It is conceivable that 
LYAR may be involved in regulating ribosomal gene 
transcription. On the other hand, LYAR may also func- 
tion in other cell compartments either during different 
stages of development or different stages of the cell cy- 
cle. Identification of the DNA sequences interacting 
with LYAR should be informative about the target genes 
for LYAR action. Ribosomal genes are candidate targets 
for LYAR action because of its subcellular location. In 
addition, general methods can be employed that have 
been developed to identify the DNA-binding sites of any 
putative DNA-binding protein (Kinzler and Vogelstein 
1989; Mavrothalassitis et al. 1990). 
Induction of LYAR during oncogenic transformation 
The LYAR gene is highly expressed in all T and B leu- 
kemia cells tested but is not detected in normal thymus 
and bone marrow cells. During the radiation induction of 
thymic leukemias, the LYAR gene was induced in 
preleukemic thymocytes and remained active in acute 
leukemic thymocytes (Fig. 5). Therefore, LYAR expres- 
sion seemed to be associated with the early stages of 
oncogenic transformation. 
The results described above raised the possibility that 
LYAR may be associated with cell proliferation in gen- 
eral. However, several ines of evidence indicated that 
the LYAR gene was not expressed uring proliferation of 
some normal cells. First, actively proliferating cells are 
present in bone marrow (>20%1, yet no or very low lev- 
els of LYAR expression were detected in bone marrow 
Table 2. Oncogenicity test of LYAR in NIH-3T3 cells 
Tumor 
Cells a 8 weeks 14 weeks 
Experiment 1 
Neol 0/5 1/5 c 
Vlyl2 4/5 5/5 (3) a 
Vneo45 0/5 0/5 
Experiment 2 
Vneo22 0/5 1/5 
Vlyl2 4/5 4/5 (2) 
Vly22 2/5 3/5 (1 } 
Vly36 3/5 3/5 (21 
Vlyl2T e 10/10 10/10 (8} 
"NIH-3T3 cells were transfected with a neomycin resistance 
gene (Neol), with a LYAR cDNA in a retroviral vector (Vlyl2, 
Vly22 and Vly36}, or with the same retroviral vector expressing 
the neo gene (Vneo22 and Vneo45}, and G418-resistant cells 
were cloned and analyzed. 
bAbout 2 x 105 cells were injected subcutaneously into each 
nu/nu mouse. Tumors at the sites of injection were scored 
weekly. 
r tumors {<0.5 cm in diam.} appeared around the four- 
teenth week postinjection, when tumors observed at the eighth 
week were bigger than 3 cm in diam. 
aNumber of mice that died from tumors. 
eTumor cells derived from {experiment 1}Vlyl2-injected nu/nu 
mice. 
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cells (Fig. 5). Second, AR1 (an IL-2-dependent CTL line) 
can proliferate efficiently in the presence of IL-2, but no 
LYAR expression was detected in AR1 cells (Fig. 5). 
Therefore, LYAR expression appeared to be associated 
with abnormal cell growth. 
Interestingly, the LYAR gene was expressed at high 
levels in ES cells and in a number of fetal tissues includ- 
ing fetal liver and fetal thymus (Fig. 6; L. Su and I.L. 
Weissman, unpubl.). This suggests that the LYAR func- 
tion may be important during normal fetal development. 
The expression of LYAR in immature spermatocyte c lls 
also suggests that LYAR may be involved in growth of 
undifferentiated cells or early cell differentiation. 
LYAR: a novel nucleolar oncoprotein 
We demonstrated that NIH-3T3 cells overexpressing the 
LYAR cDNA from a retrovirus vector, when injected 
into nu/nu mice, had higher activity (higher frequency 
and shorter latent period) for tumor formation. There- 
fore, LYAR behaved like an oncoprotein. However, the
cells overexpressing LYAR did not grow like completely 
transformed cells in vitro, that is, no focus formation or 
anchorage-independent growth in agarose colony assay 
was detected (data not shown). 
Although it has been shown that the nucleoli of tumor 
cells may be distinguishable from those of normal cells 
(Busch et al. 1979, 1986) very little is known about the 
significance of these differences. Proliferating cells and 
tumor cell-specific nucleolar antigens have been identi- 
fied. Their precise role in cell proliferation, in transfor- 
mation, or in the maintenance of tumorigenicity is not 
clear (Yeoman et al. 1976; Tan 1982; Mathews et al. 
1983). 
Whereas different ypes of genetic alterations may all 
lead to altered expression r function of cell-growth reg- 
ulatory genes and to abnormal growth, it is generally 
believed that more than o e event is required to lead to 
the neoplastic transformation of a normal cell to a ma- 
lignant one (Land et al. 1983; Weinberg 1989). It is con- 
ceivable that LYAR may partly transform cells and ren- 
der them more sensitive to other transformation events 
that lead to malignant transformation. Alternatively, 
LYAR may complement a pre-existing transformation 
event present in the NIH-3T3 fibroblast cell line to cause 
malignant ransformation. Experiments testing the on- 
cogenic potential of LYAR in vivo or in primary cells are 
in progress. 
A new zinc finger-encoding oncogene, mdm-2, has 
been reported recently (Fakharzadeh et al. 1991). The 
mdm-2 protein has two zinc fingers of CXXC/CXXC 
type. The mdm-2 gene is found to be overexpressed in a 
number of tumor cells. Like LYAR, overexpression of 
mdm.2 in NIH-3T3 cells does not lead to morphologic 
transformation i vitro, but it can increase tumorigenic- 
ity of the cells in nu /nu  mice. Two recent studies have 
reported that mdm-2 can physically interact with and 
modulate the function of the p53 protein to affect cell 
growth (Momand et al. 1992; Oliner et al. 1992). 
Mater ia ls  and methods  
Cell lines 
NIH-3T3 cells, COS-7 cells, and EF cells are maintained in Dul- 
becco's modified Eagle medium supplemented with 10% fetal 
bovine serum (FBSI (Sigma). The T leukemia cells EL4, VL3.1, 
and BW5147; B leukemia cells L2-1, 200-2, RAWll2; and the 
bone marrow-derived stromal cell line AC-6 are maintained in 
RMPI-1640 supplemented with 10% FBS. The CTL line AR-1 
cells are cultured in RMPI-1640 supplemented with 10% FBS 
and 5% RAT T-stim with concanavalin A (Collaborative Re- 
search, Inc.). 
Molecular cloning and DNA sequence analyses 
A kgtl 1 cDNA library of EL4 cells (a gift from T. St. John, ICOS, 
Seattle, WA) was screened with a monoclonal antibody against 
the mouse Ly-1 antigen 157.3.1; Ledbetter and Herzenberg 
19791, as described previously (St. John et al. 1986}. LYAR clones 
were used to screen the library to get the full-length LYAR 
cDNA. DNA sequence was obtained by subcloning the cDNA 
into M13mpl8 and M13mpl9. Both strands were sequenced by 
chain termination using the Sequenase 2.0 kit (U.S. Biochemi- 
cals). 
The DNA sequence was analyzed on the Stanford Cell Biol- 
ogy VAX computer, with the Wisconsin GCG programs, and on 
the CMGM computer at Stanford, with the IntelliGenetics pro- 
grams. 
Northern blot analyses 
Total RNAs from cell lines or fresh tissues were purified, and 15 
~g of total RNA was used for each Northern blot analysis (Ausu- 
bel et al. 1989). A human B-actin cDNA (a kind gift from M. Hu, 
Stanford University, CA) was used as probe to standardize the 
amount of RNA from each sample. 
In situ hybridization 
In situ hybridization was performed essentially as described 
(Wilkinson et al. 1987) except hat the LYAR cDNA in pBlue- 
script KS or SK (Stratagene) was used as template for T7 RNA 
polymerase transcription to generate a sense or antisense RNA 
probe labeled with s-aSS-labeled UTP. 
LYAR fusion proteins and antibody production 
The entire coding region of LYAR was fused with the bacterial 
GST gene, and the fusion protein was overexpressed and puri- 
fied as described (Smith and Johnson 1988). The purified fusion 
protein was used to immunize rabbits or rats for polyclonal or 
monoclonal antibody production, respectively. Purified LYAR 
protein fused with the bacterial maltose binding protein (MBP, 
New England Biolabs) was used for screening anti-LYAR-posi- 
tire antibodies by ELISA (Harlow and Lane 1988). The antibod- 
ies were purified on protein A or protein G affinity column 
(Harlow and Lane 19881. 
Protein analysis 
Total cell extract from l0  6 cells was analyzed by Western blot as 
described (Harlow and Lane 19881. The rabbit anti-LYAR serum 
or preimmune serum was used at different dilutions. Protein A 
conjugated with horseradish peroxidase (HRP, Sigma) was used 
as the second-stage r agent, and an ECL Western blot detecting 
kit IAmersham) was used. 
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Immunoprecipitation was performed essentially as described 
[Harlow and Lane 19881. Briefly, cell extract labeled with 
[aSS]methionine [5 x 106 cpml was used for each reaction with 
the antisera, and protein A-Sepharose (Sigma) was used to pellet 
the rabbit IgG. 
For indirect immunofluorescence staining, it was adapted 
from the protocol described (Harlow and Lane 1988). Cells 
grown on chamber slides ( at -70% confluence) were washed 
with PBS and fixed in 3.7% formaldehyde for 10 rain. The cells 
were then washed with PBS again and treated with acetone for 
2 rain. After washing with H~O and PBS, the anti-LYAR anti- 
body or control antibody was diluted in PBS and incubated with 
the cells for 60 rain at room temperature. The cells were then 
washed three times with PBS and incubated with rhodamine- 
labeled goat anti-rabbit IgG antibody for 60 rain. After the sec- 
ond antibody staining, the cells were incubated with Hoechst 
dye 33342 (CalBiochem) at 400 nM for 15 rain at room temper- 
ature, followed by three washes with PBS. A Nikon (Nikon, Inc.) 
microscope was used for imaging and photography. 
Radiation induction of T-cell leukemia in C57B1/Ka mice 
The radiation protocol was as described (Kaplan and Brown 
1954). Cells from preleukemic thymuses were isolated from 
mice 12-16 weeks after the initial irradiation. Thymocytes at 
this stage contain a subpopulation that has acquired leuke- 
mogenie potential but is not fully transformed. Leukemic thy- 
mocytes were isolated from mice 20 weeks after the initial ir- 
radiation, when the mice had visible tymphoma in the thymus. 
Transient expression of LYAR cDNA in COS-7 cells 
LYAR cDNA was cloned into pSDD2 vector (a gift from D. 
Denny, Stanford University, CA) and transfected into COS-7 
cells by the DEAE-dextran method as described (Ausubel et al. 
1989). 
Stable transfection of LYAR cDNA in NtH-bT3 cells 
LYAR cDNA cloned in a retrovirus vector (a gift from C. Shih, 
Systemix, Palo Alto, CA) was cotransfected with pGKneo (a gift 
from E. Li, MIT, Cambridge, MA) into NIH-bT3 cells, and G418- 
resistant cells were cloned. Cells transfected with pGKneo 
alone or with the same retrovirus vector expressing the neomy- 
cin resistance gene w re also selected and cloned. 
Tumorigenicity est in nu/nu mice 
Stable transfectants were expanded, and 2 x l0 s cells were in- 
jected subcutaneously into each nu/nu mouse. Tumors at the 
injection sites were monitored weekly for at least 14 weeks. 
Mapping the chromosomal location of the L YAR gene 
with recombinant inbred mice 
A RFLP was identified for the LYAR probe between the inbred 
mouse strains C57B1/6 and DBA using the restriction enzymes 
KpnI and ApaI. Segregation of this RFLP marker was examined 
in 21 BXD iecombinant inbred strains, kindly provided by Ben- 
jamin Taylor (Jackson Laboratory; Bar Harbour, ME). The re- 
sultant pattern was compared with 144 other markers on 16 
chromosomes from the BXD strains (Taylor 1989). Linkage was 
determined by X ~ analysis. 
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